IQN Path
IFPMA supports IQN Path, a leading international consortium working to improve the quality and reach of biomarker testing – an essential foundation for precision oncology.
Overview
As cancer care becomes increasingly guided by molecular insights, many health systems, especially in low‑ and middle‑income countries (LMICs), still face major gaps in diagnostic capacity, infrastructure, and workforce expertise.
Our role
Through this partnership, IFPMA helps:
- Strengthen global collaboration by connecting IQN Path with biopharmaceutical companies, health‑industry partners, and NGOs active on the ground.
- Support evidence‑based solutions that identify barriers to biomarker testing and propose practical reforms to accelerate precision oncology uptake.
- Elevate precision oncology in global health policy, ensuring that equitable access to diagnostics and targeted treatments becomes a shared priority across governments, advocacy groups, and international institutions.
- Enable implementation efforts by contributing to multi‑stakeholder work that maps country‑level needs and offers tailored recommendations for improving diagnostic systems.
Why this matters
Precision oncology can only succeed when all patients – regardless of geography – have access to reliable, high‑quality biomarker testing. By supporting IQN Path’s research, convening power, and technical work, IFPMA helps advance a future where innovative cancer care can benefit more people, in more places.
IFPMA and our sister association EFPIA provide financial support for this work, with in-kind support from MedTech Europe.
C/Can and IQN Path unite to advance access to quality biomarker testing in LMICs
Through this project, IQN Path is collaborating with C/Can to turn best practices on cancer diagnostics into reality on the ground.
Learn more
Explore IQN Path’s work, expert groups, and publications – and see how the consortium is shaping the future of precision oncology.